Targeted Clinical Trials The LOIS-3D preclinical system and the LOUISA-3D clinical system are already undergoing validation, indicating a market entry pathway with research institutions and cancer centers that may require imaging solutions for small animal studies and dense breast cancer diagnostics, presenting a direct sales opportunity to academia and translational research labs.

Customizable Components The company offers customizable analog and digital electronics and software, enabling upsell or cross-sell opportunities to existing customers who require tailored optoacoustic imaging modules, sensors, or integration with their current lab workflows.

Regulatory Pathways Vertically integrated from R&D to regulatory certification, TomoWave can position itself as a one-stop vendor for institutions seeking end-to-end support, potentially shortening procurement timelines for research and early clinical validation projects.

Growing Market Entry With a newly established sales team and distributors and a first commercial product for preclinical research, there is momentum to expand into additional academic centers, biotech firms, and contract research organizations focusing on optoacoustic imaging and breast cancer diagnostics.

Revenue Levers Current revenue range indicates a growing but small-to-mid-stage company; leveraging clinical validation data, pilot programs, and component sales could drive higher average deal sizes, recurring sales, and potential grant-funded collaborations with universities and hospitals.